Pharmaceuticals News and Research

RSS

Canada first country to approve cannabis based painkiller

Canada has become the first country to approve a cannabis based painkiller for multiple sclerosis (MS) patients.

21 Jun 2005

CSIRO hyperspectral imaging software can be used by pharmaceutical companies for production line quality assurance

New CSIRO imaging software means consumers could be confident their tablets contain exactly what their packaging says.

21 Jun 2005

Software that automatically assesses a drug's effect on nerve cells

Potential new drugs for neurological disorders like Parkinson's are being screened faster thanks to world-leading CSIRO software that automatically assesses a drug's effect on nerve cells.

21 Jun 2005

New cardiovascular drug derived from Dan Shen (Saliva miltiorrhiza)

Through a large number of clinical trials over the past 3 years, researchers from the CAS Shanghai Institute of Materia Medica (SIMM) have developed a new cardiovascular drug with a definite effective component extracted from Dan Shen (Saliva miltiorrhiza), a medicinal herb widely used in China.

21 Jun 2005

FDA severely limits access to cancer drug Iressa

After Food and Drug Administration (FDA) officials agreed with studies showing lung cancer drug, Iressa, did not help patients live longer, drug company AstraZeneca said it would severely limit access to its drug.

20 Jun 2005

Brazil patent seizure threatens global trade and public health

With a number of other non-profit groups, ITSSD is calling attention to Brazil's threat to break U.S. patents on American AIDS drugs used as part of Brazil's government-funded treatment program.

19 Jun 2005

Fine tuning drug levels in neuroblastoma patients is effective

Monitoring and fine tuning the levels of the cancer drug topotecan in children with neuroblastoma holds promise for maximizing the drug's effectiveness while reducing its toxicity, according to investigators at St. Jude Children's Research Hospital.

19 Jun 2005

Melbourne researchers take head lice treatment to the world

A new Victorian biotechnology company, Hatchtech, announced at BIO 2005 that its technology is the first in the world to kill 100% of head lice eggs. International clinical trials are expected to begin within a year and the product may be on market shelves within three years.

19 Jun 2005

Australian scientists develop unique animal model for asthma

The State Government of Victoria, Australia has announced that Melbourne veterinary scientists have developed a unique animal model for asthma that may help drug companies fast track the creation of therapies for the disease.

19 Jun 2005

Stem cells to solve blood shortage problems

The State Government of Victoria, Australia announced that Melbourne scientists at Monash University have developed a unique technology that can grow large numbers of blood cells from human embryonic stem cells.

19 Jun 2005

Findings may help scientists improve the existing vaccine for yellow fever

In one of the first molecular studies of the human antibody response to yellow fever, Howard Hughes Medical Institute (HHMI) researchers and their colleagues have found the crucial bit of virus that people's immune systems need to spot and quash this often-fatal re-emerging disease.

16 Jun 2005

Fine tuning drug levels in neuroblastoma patients is effective

16 Jun 2005

The PATH Malaria Vaccine Initiative welcomes G8 plan for development of APCs

A call to end the disease, the poverty, and the suffering in Africa is being heard around the world today. The recently announced G8 Finance Ministers’ Conclusions on Development reiterated and responded to that call.

16 Jun 2005

First demonstration of a vaccine for Parkinson's

Researchers at the University of California, San Diego (UCSD) School of Medicine working with scientists at Elan Pharmaceuticals, have reported promising results in mice of a vaccine approach to treating Parkinson’s and similar diseases. These results appear in the June edition of the journal Neuron.

15 Jun 2005

Report on Hispanics and genes, culture, and medicines highlights the rise of individualized medicine

"The FDA's review today of BiDil could make it the first drug approved specifically for African Americans and marks the end of 'one-size-fits-all' medicine," said Dr. Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health (the Alliance), the nation's leading Hispanic health advocacy group.

15 Jun 2005

Nanotechnology used to smuggle a powerful chemotherapeutic drug inside tumor cells

University of Michigan scientists have created the nanotechnology equivalent of a Trojan horse to smuggle a powerful chemotherapeutic drug inside tumor cells - increasing the drug's cancer-killing activity and reducing its toxic side effects.

15 Jun 2005

The most frequently used drugs for treating chronic insomnia have never been approved for that purpose

Vaughn McCall, M.D., M.S., professor and chairman of the Department of Psychiatry and Behavioral Medicine, told a special consensus panel at the National Institutes of Health (NIH) that he could find no evidence that randomized controlled clinical trials had ever been conducted for five of the 10 pharmaceuticals prescribed most often for chronic insomnia.

14 Jun 2005

Royal Pharmaceutical Society responds to over the counter medication report

Responding to the British Medical Association's (BMA) report, Over the counter medication, David Pruce, Director of Practice and Quality Improvement, the Royal Pharmaceutical Society of Great Britain, said:

14 Jun 2005

Chemokine Therapeutics granted new U.S patent

Chemokine Therapeutics has announced that it has been granted U.S. Patent No. 6,875,738 relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angiogenesis. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells.

14 Jun 2005

Patients with newly diagnosed type 2 diabetes should be screened for retinopathy

Diabetic retinopathy has been found in nearly 8 percent of pre-diabetic participants in the Diabetes Prevention Program (DPP), according to a report presented today at the American Diabetes Association's 65th Annual Scientific Sessions.

12 Jun 2005